{"entity":{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","aka":[],"tldr":"A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.","summary":"Yuankai Shi is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. He has led many of China's registrational trials of domestically developed targeted agents and antibodies, serving as principal investigator for phase 3 trials of EGFR inhibitors, PD-1 antibodies and lymphoma therapies. His publications include the pivotal phase 2 study of chidamide in relapsed or refractory peripheral T-cell lymphoma, the ICOGEN non-inferiority trial of icotinib against gefitinib in previously treated lung cancer, and the PIONEER molecular epidemiology study of EGFR mutations in Asian patients with lung adenocarcinoma. He leads the hospital's clinical pharmacology and drug development programme.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20Y%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Lung cancer","Lymphoma","Drug development","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20Y%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20lung%20cancer"}],"papers":[{"title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv237"},{"title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70355-3"},{"title":"A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)","journal":"Journal of Thoracic Oncology","year":2014,"doi":"10.1097/jto.0000000000000033"}]},"route":"/people/shi-yuankai/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/"}]}}